Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Pharmacovigilance Market Outlook (2023 to 2033)

The pharmacovigilance market is anticipated to increase, from US$ 6.87 billion in 2023 to US$ 23.31 billion in 2033. According to FMI, the market is expected to expand at a CAGR of 13% over the course of the projected period.

As a result of the development of chronic illnesses, which necessitates the use of pharmacovigilance more frequently, there is an increased demand for novel pharmaceuticals that are created through meticulous clinical research.

It is anticipated that demand for pharmacovigilance services is likely to increase, as adverse drug reactions (ADRs) happen more frequently. Additionally, a combination of rising expectations for drug safety and rising patient consumption of medications is the main driver of the pharmacovigilance market expansion during the forecast period.

Moreover, clinicians must perform comprehensive tests and data analysis to assure minimal adverse effects, which forces big pharmaceutical companies to work with renowned pharmacovigilance service providers.

Attributes Details
Historical Value (2022) US$ 6.28 billion
Current Year Value (2023) US$ 6.87 billion
Expected Forecast Value (2033) US$ 23.31 billion
Historical CAGR (2018 to 2022) 7.9%
Projected CAGR (2023 to 2033) 13%

Furthermore, the advent of COVID-19 has given pharmaceutical companies a variety of opportunities to create novel vaccines, resulting at the beginning of multiple clinical trials. This function now makes it easier to enter the pharmacovigilance market, which is the most important stage of any medicine development process.

Therefore, during the anticipated time, the growth of the pharmacovigilance market is likely to be supported by such favorable initiatives.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

What Strives The Pharmacovigilance Market?

Drivers As a result of increased public awareness of OTC drug adverse effects; there is a greater need for safer drugs. This feature is anticipated to accelerate the demand for pharmacovigilance due to the monitoring of medications that are readily available on the market for potential adverse drug responses.
Example Every year, the Uppsala Monitoring Centre (UMC) runs a social media campaign to raise patient and public awareness of the importance of reporting suspected ADRs and the safe use of medications.
Drivers Credible information on medicines, their correct usage, side effects, and other topics are transmitted more widely thanks to government initiatives, programs, and pharmaceutical firms' awareness campaigns.
Example The American Society of Pharmacovigilance officially launched a national awareness campaign in March 2021 to encourage people who have experienced adverse drug events to share their experiences and foster community support, while praising organizations and healthcare professionals for talking about how they can support medication safety.
Drivers Regarding time restrictions and the facilities that an outsourced service may supply, outsourcing offers clear benefits to manufacturing organizations. Additionally, outsourcing permits businesses to customize services in accordance with their needs, accelerating the evaluation process.
Example On International Patient Safety Day in 2019, Bayer unveiled the SafeTrack digital application, which allows users to report negative incidents. The program is a simple, practical internet tool that enables prompt reporting of an AE.

Lack of Awareness:

Inconsistent reporting is a result of patients' lack of knowledge regarding adverse events (AE). The patient typically becomes worried and reports all of their symptoms as an adverse event (AE). But not all reported adverse events (AEs) are necessarily serious, which forces committees in pharmaceutical firms to make bad decisions that result in the drug's withdrawal.

The necessary software, services, and training are missing in low- and middle-income nations for these specialized services. In addition, little is being done by governments and pharmaceutical firms to raise awareness of AE reporting. The pharmacovigilance market expansion in low- and middle-income nations is predicted to be constrained by these issues.

Data Security:

Moreover, the pharmacovigilance market may see a slowdown during the projected period due to issues like the high risk associated with data security, the absence of global regulatory harmonization, and the lack of data standardization for adverse event collecting.

Comparative View Of Adjacent Pharmacovigilance Market

Pharmacovigilance Market:

Differentiating Aspects Pharmacovigilance Market
CAGR (2023 to 2033) 13%
Projected Market Value in 2033 US$ 23.31 billion
Growth Factors The primary factors driving the market are escalating patient medicine usage and escalating expectations for drug safety.
Opportunities Government programs, efforts, and pharmaceutical companies' awareness campaigns help spread reliable information about drugs, their proper use, side effects, and other topics, while also creating business opportunities.
Key Trends While focusing on technological advancement, market participants are constantly creating safety services to promote the acceptance of pharmacovigilance services.

Pharmaceuticals Excipients Market:

Differentiating Aspects Pharmaceuticals Excipients Market
CAGR (2023 to 2033) 6%
Projected Market Value in 2033 US$ 15.90 billion
Growth Factors The rapidly expanding pharmaceutical industry and the growing acceptability of orphan drugs are driving up the demand for pharmaceutical excipients.
Opportunities The pharmaceutical business requires novel functional excipients, which is likely to spur market innovations and boost pharmaceutical excipient sales
Key Trends Due to effective strategy, industry leaders regularly release a variety of cutting-edge excipients, as well as modified categories of excipients already on the market

Pharmaceutical Drug Delivery Market:

Differentiating Aspects Pharmaceutical Drug Delivery Market
CAGR (2023 to 2033) 6.4%
Projected Market Value in 2033 US$ 3.5 trillion
Growth Factors The industry is expanding as a result of leading market participants investing more money in the research and development of pharmaceutical drug delivery systems.
Opportunities Self-administration and home care are expected to offer pharmaceutical medication delivery systems significant future opportunities.
Key Trends The pharmaceutical medication delivery system has been expanded to include a new class of medicines with huge potential for reducing cancer, diabetes, and other sickness treatments.

Businesses are engaging with one another more regularly due to new platforms like the cloud and social media. As a result, the complexity of attacks, the seriousness of breaches, and potential threats to data security have all increased.

It is crucial for the healthcare industry to protect the proprietary and confidential information linked to services and goods, due to the serious risk of their confidentiality being compromised. Regulatory requirements for conducting clinical trials and post-marketing surveillance are also anticipated to increase demand for pharmacovigilance services during the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Segmentation Outlook

Segment 2022 Value Share in Global Market
Phase IV 75.1%
Spontaneous Reporting 31.1%

Why are Phase-IV Clinical Trials acquiring Importance in Pharmacovigilance Market?

With a revenue share of more than 75.1% in 2022, the phase IV (post-marketing) segment took the whole market by storm.

These treatments serve as an extra layer of safety for the medications undergoing clinical trials. Due to intense drug testing on a wide demographic patient base of the highest significance following the commercialization of the drug, it is envisaged that the data gathered and evaluated during this stage is of the highest relevance.

Phase-IV clinical trials have gained substantial importance in the pharmacovigilance market due to their role in post-market surveillance. Conducted after a drug's approval, these trials monitor its safety and efficacy in a broader patient population, offering real-world evidence beyond controlled settings. They are vital for identifying rare adverse events and interactions with different patient profiles, leading to better risk management and patient safety.

Phase-IV trials provide data on a drug's comparative effectiveness, supporting healthcare decision-making and regulatory compliance. They contribute to drug lifecycle management by facilitating label updates, new indications, and market access negotiations. Moreover, Phase-IV trials play a critical role in generating real-world data and evidence, complementing traditional clinical trial information and helping assess a drug's cost-effectiveness. Hence, Phase-IV clinical trials have become indispensable for continuous drug evaluation, ensuring safer and more effective healthcare practices.

Why is Targeted Spontaneous Reporting Attracting Major Investments in the Pharmacovigilance Market?

In 2022, spontaneous reporting accounted for the biggest share with almost 31.1%.

This is because the technique is widely used in the detection of novel, severe, and uncommon ADRs and is both effective and affordable. The extensive use of monitoring reports produced using this methodology by the pharmaceutical industry and regulatory bodies is another factor contributing to the segment's rapid expansion.

Spontaneous reporting plays a vital role in the pharmacovigilance market since it enables the early detection of adverse events related to medications and medical products. This ensures timely interventions to protect patient safety. Regulatory compliance mandates pharmaceutical companies to implement robust pharmacovigilance systems, including effective spontaneous reporting mechanisms. By adhering to these regulations, companies demonstrate their commitment to public health and enhance their market reputation.

The continuous growth of drug pipelines necessitates improved pharmacovigilance capabilities. This leads to investments in technologies and data analytics that streamline spontaneous reporting processes. Additionally, global harmonization efforts in pharmacovigilance standards drive companies to invest in infrastructure and capabilities to meet international requirements. Furthermore, the industry's shift toward patient-centric care has elevated the importance of listening to patients' experiences and concerns. Spontaneous reporting empowers patients to participate actively in drug safety by reporting adverse events they encounter.

What is the Regional Analysis of the Pharmacovigilance Market?

North America Outlook

North America held the largest revenue share of over 30.0% in 2021 owing to the presence of key pharmaceutical and medical devices players, contributing to the overall revenue in this region. The rising level of drug abuse and associated adverse drug reactions is a leading cause of morbidity and death.

This acts as a high-growth rendering factor for the pharmacovigilance market in North America. Rising investment in novel drug development by major players is also anticipated to propel regional market growth.

Country United States
2022 Value Share in Global Market 30.9%

The United States has one of the leading pharmaceutical markets globally, making it a crucial region for pharmacovigilance activities. The country's stringent regulatory framework and a strong emphasis on patient safety have fueled the market growth. The increasing number of adverse drug events and drug recalls has led pharmaceutical companies and regulatory authorities to prioritize pharmacovigilance activities. The United States Food and Drug Administration (FDA) plays a vital role in pharmacovigilance, setting strict guidelines for drug safety monitoring and post-market surveillance. The FDA's oversight and commitment to patient safety have contributed to shaping the pharmacovigilance practices in the country. The United States has seen a growing focus on patient-centric pharmacovigilance, where patient-reported outcomes and experiences are actively sought and valued. As the pharmaceutical industry continues to innovate and introduce new therapies, the importance of robust pharmacovigilance practices is likely to only grow in ensuring the safe use of medications in the United States.

Europe Outlook

Currently, a number of clinical trials are anticipated to be carried out to evaluate the effectiveness of different medication candidates, offering up new growth opportunities for UK-based providers of pharmacovigilance solutions.

The London Trials, which are scheduled to start in the summer of 2021, is an example. The Hammersmith Medicines Research organization is managing these trials.

Country Value CAGR (2023 to 2033)
United Kingdom 12.1%
Country 2022 Value Share in Global Market
Germany 6.9%

The increasing adoption of personalized medicine in the United Kingdom has led to a surge in the number of medications tailored to individual patient profiles. This trend necessitates rigorous pharmacovigilance efforts to monitor patient responses and identify any adverse reactions specific to certain genetic groups. Healthcare stakeholders in the United Kingdom are increasingly relying on real-world evidence to complement clinical trial data. Pharmacovigilance initiatives are leveraging RWE to gain deeper insights into drug safety and efficacy in real-world settings, thereby improving patient outcomes. The expanding pharmaceutical sector in the United Kingdom, driven by research and development activities, has increased the number of drugs reaching the market. This growth has amplified the demand for pharmacovigilance services to ensure comprehensive drug safety monitoring.

As a leader in innovation and technology, Germany has adopted advanced pharmacovigilance tools such as artificial intelligence, machine learning, and big data analytics to streamline adverse event reporting and signal detection. This has improved efficiency and accuracy in identifying potential safety issues with drugs. The rise in biopharmaceutical companies in Germany has fueled the need for pharmacovigilance services. Biologics require specialized safety monitoring, leading to an increased demand for expert pharmacovigilance support. Germany boasts a robust and well-organized healthcare system. Its comprehensive network of hospitals, clinics, and healthcare professionals ensures timely and accurate reporting of adverse drug reactions. This is contributing to the effectiveness of pharmacovigilance efforts.

Asia Pacific Outlook

Due to the abundance of outsourcing companies, Asia Pacific is anticipated to experience the quickest CAGR during the projection period. Improvements in productivity, cost-effectiveness, and resource sharing, as a result, are predicted to drive up regional demand for pharmacovigilance in the ensuing years.

The regional market is also being driven by expanding investments, rising spending among patients, and supportive government activities for satisfying population needs.

Country Value CAGR (2023 to 2033)
China 16.8%
India 15.4%
Country 2022 Value Share in Global Market
Japan 5.1%

As one of the world's leading pharmaceutical markets, China has witnessed significant growth in its pharmacovigilance sector. The pharmaceutical industry's rapid growth in China directly impacts the pharmacovigilance market. Increased drug production and consumption necessitate more stringent pharmacovigilance measures. China has embraced technological innovations in healthcare, including AI and big data analytics. These advancements have enabled faster and more accurate identification of ADRs, improving overall drug safety surveillance. China's rich history of traditional medicine has led to unique challenges in pharmacovigilance. The coexistence of traditional and modern medicines requires a tailored approach to monitoring and reporting adverse events. The growth of e-commerce in China has also affected pharmacovigilance efforts. It has opened up new channels for the sale of pharmaceutical products, necessitating robust monitoring to detect and address potential safety issues.

The pharmacovigilance market in India has experienced significant growth in recent years. As India's pharmaceutical industry continues to grow, the importance of pharmacovigilance becomes even more effective in maintaining drug safety standards. With an increasing population and growing middle class, the demand for quality healthcare services in India has surged. As a result, the market has witnessed higher demand for drug safety monitoring and reporting. India has emerged as a preferred destination for global pharmaceutical companies to outsource their Pharmacovigilance processes. The availability of a skilled workforce and cost-effectiveness have made India an attractive outsourcing hub for Pharmacovigilance services. India has a significant market for over-the-counter drugs. Since some OTC drugs may not require a prescription, monitoring their adverse effects can be challenging. Pharmacovigilance efforts need to encompass both prescription and non-prescription drugs.

Japan has a strong healthcare infrastructure and a well-established reporting system for adverse drug reactions. The Japanese population is proactive in reporting ADRs, which has led to an increase in the number of pharmacovigilance activities. Many pharmaceutical companies in Japan are outsourcing pharmacovigilance services to specialized third-party providers. This trend is driven by the need to focus on core competencies and ensure compliance with stringent regulations. Japan possesses one of the most prominent aging populations globally. As the elderly are more susceptible to adverse drug reactions, there is a growing focus on monitoring drug safety in this demographic. With the increasing influence of technology, the market in Japan is expected to remain dynamic and essential for ensuring drug safety during the forecast period.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

How Are Startups Utilising The Potential In The Pharmacovigilance Market?

Service providers from many regions are developing cutting-edge technologies to support the pharmacovigilance business. The technology comprises real-time products, AI-based solutions, and fresh drugs in the pipeline.

For instance:

  • HEPAprint, a British business, creates predictive software to stop negative medication reactions. The software forecasts the potential effects medications may have on particular genetic markers using artificial intelligence (AI) and individual genetic data.
  • Pharmacovigilance is supported by digital Software-as-a-Service (SaaS) from the German startup MEDIKURA Digital Health. The start-up makes it possible to collect structured data from end users and includes all required parties, including pharmacists, physicians, patients, and manufacturers.
  • AI-based pharmacovigilance solutions are offered by Indian firm Navro Technology Solutions. The business enables pharmaceutical companies to shorten the time required to report adverse drug reactions with the aid of deep learning and AI.

What Is The Competitive Analysis Of The Pharmacovigilance Market?

The patent expiration of branded pharmaceuticals is encouraging new clinical trials to discover new candidates, which is causing prominent companies in the pharmacovigilance market to see an improvement in their revenue prospects. Some market participants use collaborations with top pharmaceutical companies as a key strategy.

Collaboration and Business Services

  • In May 2023, JNPMEDI introduced its latest drug safety management solution, 'Maven Safety.' This innovative platform optimizes work efficiency while maintaining cost-effectiveness by offering a subscription-type SaaS solution. It allows users to select and utilize only the necessary functions based on the project's scale.
  • In March 2022, The Drug Safety Research Unit (DSRU) inaugurated the Institute of Pharmacovigilance Sciences on a global scale. This significant launch signifies a substantial expansion in the DSRU's proficiency and its 40-year history of conducting methodological and pharmacovigilance research.
  • In February 2022, Cognizant established a partnership with Medable Inc. to provide combined clinical research solutions utilizing Medable's software-as-a-service platform, focused on decentralized clinical trials.
  • In February 2022, LINK Medical and Viedoc joined forces in a partnership initiated by Viedoc with the aim of enhancing trial efficiency for both LINK Medical and its clients. This collaboration facilitates an ongoing exchange of experiences, requirements, and ideas, as well as the opportunity to test and implement new features.
  • In December 2021, through a managed services agreement with Springer Nature, Wipro Limited revealed its plans to introduce regulatory literature monitoring services tailored for pharmaceutical companies. This move effectively expanded the range of services offered by the company.
  • In September 2021, IQVIA and NRx Pharmaceuticals entered into a groundbreaking collaboration. The objective was to offer pharmacovigilance services and medical information in readiness for potential regulatory actions.
  • In June 2021, SSI Strategy, LLC revealed its acquisition of Fiore Healthcare Advisors, LLC. The main goal of this acquisition is to bolster SSI's already robust Clinical Research and Drug Safety services by integrating a team of skilled Safety Physicians and Clinical Research support professionals.
  • In April 2021, ResoluteAI, the science research platform, unveiled a new set of tools designed to simplify post-market surveillance and Pharmacovigilance analysis processes.
  • Accenture Plc. and UCB worked together to develop a safety solution based on Accenture's INTIENTTM Pharmacovigilance in December 2019 to utilize artificial intelligence to speed up the process of submitting individual patient safety case reports.
  • Given its significant influence in the pharmaceutical pharmaceuticals sector, Bristol-Myers Squibb (BMS) relocated a portion of its drug safety monitoring operations to India in 2017. Employees of Accenture are now running the pharmacovigilance center.

Key Players

  • Accenture Plc.
  • Bristol-Myers Squibb
  • Clinquest Group B.V.
  • Cognizant Technology Solutions
  • Covance Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc.
  • ICON Plc
  • iGATE Corporation
  • iMED Global Corporation
  • inVentiv Health Inc.
  • Novartis AG
  • PAREXEL International Corporation
  • Pfizer Inc.
  • Pharmaceutical Product Development LLC. (PPD)
  • PRA Health Sciences Inc.
  • Quintiles Transnational Holdings Inc.
  • Sanofi SA
  • Synowledge LLC
  • Wipro Ltd.

Key players like Accenture, Cognizant, and IQVIA are benefiting from improved pharmacovigilance management.

Market players are continuously developing safety services to increase the adoption of pharmacovigilance services while concentrating on technological progress. Analytics, AI, and automation have increased the effectiveness of the businesses offering pharmacovigilance services. Automation, machine learning, and artificial intelligence are likely to soon lead to a paradigm shift in pharmacovigilance due to their sophisticated technological capabilities.

Cognizant Technology Solutions, which offers a full range of patient safety services, was recently recognized as one of the top businesses in the pharmacovigilance market in April 2021. This follows the company's ongoing efforts to improve its technologically enabled products in order to better assist clients with their digital transformation.

The market is expanding further due to rising Research and Development and the rising adoption of new technologies in clinical research. For instance, industry players like IQVIA and PRA Health Sciences are expected to boost demand in the upcoming years by incorporating virtual services into the clinical trial protocol.

Rising partnerships in the industry between software suppliers and pharmaceutical firms are also anticipated to fuel the demand for pharmacovigilance.

For instance, in November 2021, Deloitte and Sanofi worked together to develop ConvergeHEALTH Safety, a next-generation adverse events case intake platform powered by artificial intelligence (AI). This platform revolutionizes pharmacovigilance and tackles some of the most urgent operational safety issues facing the sector.

Additionally, eco-pharmacovigilance has gained prominence recently and is essential for reducing the likelihood that pharmaceutical pollutants affect the environment. As a result, pharmaceutical firms might use pharmacovigilance services to lessen environmental pollution, fueling the market's expansion.

There is a significant demand for enhanced manufacturing processes, pharmacovigilance, clinical data management, streamlined Research and Development, and medical writing as a result of the market competition for the introduction of novel compounds. For EUR 1.5 million in 2020, the UK government collaborated with the American business Genpact to create an artificial intelligence tool for screening vaccine adverse drug response (ADR) data.

Key segments

By Phase of Drug Development:

  • Preclinical Studies
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Type of Methods:

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

By Service Type Provider:

  • In-house Pharmacovigilance
  • Contract Outsourcing

By Geography:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

Who are the Key Consumers of Pharmacovigilance?

Chronic illness patients are the key consumers of the global market.

How Much Can Pharmacovigilance Market Grow by 2033 in Phase of Drug Development?

Phase 4 is poised to stay attractive, projecting a significant CAGR by 2033.

What is the Current Market Valuation?

The market is estimated to secure a valuation of US$ 6.87 billion in 2023.

How Big will the Pharmacovigilance Market by 2033?

The market is estimated to reach US$ 23.31 billion by 2033.

Which End-Use Industry Holds Lucrative Opportunities?

The hospital sector holds high revenue potential.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Phase of Drug Development

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Phase of Drug Development, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Phase of Drug Development, 2023 to 2033

        5.3.1. Preclinical Studies

        5.3.2. Phase I

        5.3.3. Phase II

        5.3.4. Phase III

        5.3.5. Phase IV

    5.4. Y-o-Y Growth Trend Analysis By Phase of Drug Development, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Phase of Drug Development, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type of Methods

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Type of Methods, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type of Methods, 2023 to 2033

        6.3.1. Spontaneous Reporting

        6.3.2. Intensified ADR Reporting

        6.3.3. Targeted Spontaneous Reporting

        6.3.4. Cohort Event Monitoring

        6.3.5. EHR Mining

    6.4. Y-o-Y Growth Trend Analysis By Type of Methods, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Type of Methods, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Service Type Provider

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Service Type Provider , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Service Type Provider , 2023 to 2033

        7.3.1. In-house Pharmacovigilance

        7.3.2. Contract Outsourcing

    7.4. Y-o-Y Growth Trend Analysis By Service Type Provider , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Service Type Provider , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. South Asia and Pacific

        8.3.6. East Asia

        8.3.7. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Phase of Drug Development

        9.2.3. By Type of Methods

        9.2.4. By Service Type Provider

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Phase of Drug Development

        9.3.3. By Type of Methods

        9.3.4. By Service Type Provider

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Phase of Drug Development

        10.2.3. By Type of Methods

        10.2.4. By Service Type Provider

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Phase of Drug Development

        10.3.3. By Type of Methods

        10.3.4. By Service Type Provider

    10.4. Key Takeaways

11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Western Europe

        11.2.2. By Phase of Drug Development

        11.2.3. By Type of Methods

        11.2.4. By Service Type Provider

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Phase of Drug Development

        11.3.3. By Type of Methods

        11.3.4. By Service Type Provider

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Czech Republic

            12.2.1.4. Romania

            12.2.1.5. Rest of Eastern Europe

        12.2.2. By Phase of Drug Development

        12.2.3. By Type of Methods

        12.2.4. By Service Type Provider

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Phase of Drug Development

        12.3.3. By Type of Methods

        12.3.4. By Service Type Provider

    12.4. Key Takeaways

13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Bangladesh

            13.2.1.3. Australia

            13.2.1.4. New Zealand

            13.2.1.5. Rest of South Asia and Pacific

        13.2.2. By Phase of Drug Development

        13.2.3. By Type of Methods

        13.2.4. By Service Type Provider

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Phase of Drug Development

        13.3.3. By Type of Methods

        13.3.4. By Service Type Provider

    13.4. Key Takeaways

14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Phase of Drug Development

        14.2.3. By Type of Methods

        14.2.4. By Service Type Provider

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Phase of Drug Development

        14.3.3. By Type of Methods

        14.3.4. By Service Type Provider

    14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Phase of Drug Development

        15.2.3. By Type of Methods

        15.2.4. By Service Type Provider

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Phase of Drug Development

        15.3.3. By Type of Methods

        15.3.4. By Service Type Provider

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Phase of Drug Development

            16.1.2.2. By Type of Methods

            16.1.2.3. By Service Type Provider

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Phase of Drug Development

            16.2.2.2. By Type of Methods

            16.2.2.3. By Service Type Provider

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Phase of Drug Development

            16.3.2.2. By Type of Methods

            16.3.2.3. By Service Type Provider

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Phase of Drug Development

            16.4.2.2. By Type of Methods

            16.4.2.3. By Service Type Provider

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Phase of Drug Development

            16.5.2.2. By Type of Methods

            16.5.2.3. By Service Type Provider

    16.6. UK

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Phase of Drug Development

            16.6.2.2. By Type of Methods

            16.6.2.3. By Service Type Provider

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Phase of Drug Development

            16.7.2.2. By Type of Methods

            16.7.2.3. By Service Type Provider

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Phase of Drug Development

            16.8.2.2. By Type of Methods

            16.8.2.3. By Service Type Provider

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Phase of Drug Development

            16.9.2.2. By Type of Methods

            16.9.2.3. By Service Type Provider

    16.10. Poland

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Phase of Drug Development

            16.10.2.2. By Type of Methods

            16.10.2.3. By Service Type Provider

    16.11. Russia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Phase of Drug Development

            16.11.2.2. By Type of Methods

            16.11.2.3. By Service Type Provider

    16.12. Czech Republic

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Phase of Drug Development

            16.12.2.2. By Type of Methods

            16.12.2.3. By Service Type Provider

    16.13. Romania

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Phase of Drug Development

            16.13.2.2. By Type of Methods

            16.13.2.3. By Service Type Provider

    16.14. India

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Phase of Drug Development

            16.14.2.2. By Type of Methods

            16.14.2.3. By Service Type Provider

    16.15. Bangladesh

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Phase of Drug Development

            16.15.2.2. By Type of Methods

            16.15.2.3. By Service Type Provider

    16.16. Australia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Phase of Drug Development

            16.16.2.2. By Type of Methods

            16.16.2.3. By Service Type Provider

    16.17. New Zealand

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Phase of Drug Development

            16.17.2.2. By Type of Methods

            16.17.2.3. By Service Type Provider

    16.18. China

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Phase of Drug Development

            16.18.2.2. By Type of Methods

            16.18.2.3. By Service Type Provider

    16.19. Japan

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Phase of Drug Development

            16.19.2.2. By Type of Methods

            16.19.2.3. By Service Type Provider

    16.20. South Korea

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Phase of Drug Development

            16.20.2.2. By Type of Methods

            16.20.2.3. By Service Type Provider

    16.21. GCC Countries

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Phase of Drug Development

            16.21.2.2. By Type of Methods

            16.21.2.3. By Service Type Provider

    16.22. South Africa

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2022

            16.22.2.1. By Phase of Drug Development

            16.22.2.2. By Type of Methods

            16.22.2.3. By Service Type Provider

    16.23. Israel

        16.23.1. Pricing Analysis

        16.23.2. Market Share Analysis, 2022

            16.23.2.1. By Phase of Drug Development

            16.23.2.2. By Type of Methods

            16.23.2.3. By Service Type Provider

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Phase of Drug Development

        17.3.3. By Type of Methods

        17.3.4. By Service Type Provider

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Accenture Plc.

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Bristol-Myers Squibb

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Clinquest Group B.V.

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Cognizant Technology Solutions

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Covance Inc.

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. F. Hoffmann-La Roche Ltd.

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. GlaxoSmithKline Plc.

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. ICON Plc

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. iGATE Corporation

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. iMED Global Corporation

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

        18.1.11. inVentiv Health Inc.

            18.1.11.1. Overview

            18.1.11.2. Product Portfolio

            18.1.11.3. Profitability by Market Segments

            18.1.11.4. Sales Footprint

            18.1.11.5. Strategy Overview

                18.1.11.5.1. Marketing Strategy

        18.1.12. Novartis AG

            18.1.12.1. Overview

            18.1.12.2. Product Portfolio

            18.1.12.3. Profitability by Market Segments

            18.1.12.4. Sales Footprint

            18.1.12.5. Strategy Overview

                18.1.12.5.1. Marketing Strategy

        18.1.13. PAREXEL International Corporation

            18.1.13.1. Overview

            18.1.13.2. Product Portfolio

            18.1.13.3. Profitability by Market Segments

            18.1.13.4. Sales Footprint

            18.1.13.5. Strategy Overview

                18.1.13.5.1. Marketing Strategy

        18.1.14. Pfizer Inc.

            18.1.14.1. Overview

            18.1.14.2. Product Portfolio

            18.1.14.3. Profitability by Market Segments

            18.1.14.4. Sales Footprint

            18.1.14.5. Strategy Overview

                18.1.14.5.1. Marketing Strategy

        18.1.15. Pharmaceutical Product Development LLC. (PPD)

            18.1.15.1. Overview

            18.1.15.2. Product Portfolio

            18.1.15.3. Profitability by Market Segments

            18.1.15.4. Sales Footprint

            18.1.15.5. Strategy Overview

                18.1.15.5.1. Marketing Strategy

        18.1.16. PRA Health Sciences Inc.

            18.1.16.1. Overview

            18.1.16.2. Product Portfolio

            18.1.16.3. Profitability by Market Segments

            18.1.16.4. Sales Footprint

            18.1.16.5. Strategy Overview

                18.1.16.5.1. Marketing Strategy

        18.1.17. Quintiles Transnational Holdings Inc.

            18.1.17.1. Overview

            18.1.17.2. Product Portfolio

            18.1.17.3. Profitability by Market Segments

            18.1.17.4. Sales Footprint

            18.1.17.5. Strategy Overview

                18.1.17.5.1. Marketing Strategy

        18.1.18. Sanofi SA

            18.1.18.1. Overview

            18.1.18.2. Product Portfolio

            18.1.18.3. Profitability by Market Segments

            18.1.18.4. Sales Footprint

            18.1.18.5. Strategy Overview

                18.1.18.5.1. Marketing Strategy

        18.1.19. Synowledge LLC

            18.1.19.1. Overview

            18.1.19.2. Product Portfolio

            18.1.19.3. Profitability by Market Segments

            18.1.19.4. Sales Footprint

            18.1.19.5. Strategy Overview

                18.1.19.5.1. Marketing Strategy

        18.1.20. Wipro Ltd.

            18.1.20.1. Overview

            18.1.20.2. Product Portfolio

            18.1.20.3. Profitability by Market Segments

            18.1.20.4. Sales Footprint

            18.1.20.5. Strategy Overview

                18.1.20.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Phase of Drug Development, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Type of Methods, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by Service Type Provider , 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Phase of Drug Development, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Type of Methods, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by Service Type Provider , 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Phase of Drug Development, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Type of Methods, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by Service Type Provider , 2018 to 2033

Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Western Europe Market Value (US$ Million) Forecast by Phase of Drug Development, 2018 to 2033

Table 15: Western Europe Market Value (US$ Million) Forecast by Type of Methods, 2018 to 2033

Table 16: Western Europe Market Value (US$ Million) Forecast by Service Type Provider , 2018 to 2033

Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: Eastern Europe Market Value (US$ Million) Forecast by Phase of Drug Development, 2018 to 2033

Table 19: Eastern Europe Market Value (US$ Million) Forecast by Type of Methods, 2018 to 2033

Table 20: Eastern Europe Market Value (US$ Million) Forecast by Service Type Provider , 2018 to 2033

Table 21: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: South Asia and Pacific Market Value (US$ Million) Forecast by Phase of Drug Development, 2018 to 2033

Table 23: South Asia and Pacific Market Value (US$ Million) Forecast by Type of Methods, 2018 to 2033

Table 24: South Asia and Pacific Market Value (US$ Million) Forecast by Service Type Provider , 2018 to 2033

Table 25: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 26: East Asia Market Value (US$ Million) Forecast by Phase of Drug Development, 2018 to 2033

Table 27: East Asia Market Value (US$ Million) Forecast by Type of Methods, 2018 to 2033

Table 28: East Asia Market Value (US$ Million) Forecast by Service Type Provider , 2018 to 2033

Table 29: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 30: Middle East and Africa Market Value (US$ Million) Forecast by Phase of Drug Development, 2018 to 2033

Table 31: Middle East and Africa Market Value (US$ Million) Forecast by Type of Methods, 2018 to 2033

Table 32: Middle East and Africa Market Value (US$ Million) Forecast by Service Type Provider , 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Phase of Drug Development, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Type of Methods, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Service Type Provider , 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Phase of Drug Development, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Phase of Drug Development, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Phase of Drug Development, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Type of Methods, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Type of Methods, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Type of Methods, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by Service Type Provider , 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by Service Type Provider , 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by Service Type Provider , 2023 to 2033

Figure 17: Global Market Attractiveness by Phase of Drug Development, 2023 to 2033

Figure 18: Global Market Attractiveness by Type of Methods, 2023 to 2033

Figure 19: Global Market Attractiveness by Service Type Provider , 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Phase of Drug Development, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Type of Methods, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by Service Type Provider , 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Phase of Drug Development, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Phase of Drug Development, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Phase of Drug Development, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Type of Methods, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Type of Methods, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Type of Methods, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by Service Type Provider , 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Service Type Provider , 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Service Type Provider , 2023 to 2033

Figure 37: North America Market Attractiveness by Phase of Drug Development, 2023 to 2033

Figure 38: North America Market Attractiveness by Type of Methods, 2023 to 2033

Figure 39: North America Market Attractiveness by Service Type Provider , 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Phase of Drug Development, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Type of Methods, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by Service Type Provider , 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Phase of Drug Development, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Phase of Drug Development, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Phase of Drug Development, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Type of Methods, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Type of Methods, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Type of Methods, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by Service Type Provider , 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by Service Type Provider , 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Service Type Provider , 2023 to 2033

Figure 57: Latin America Market Attractiveness by Phase of Drug Development, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Type of Methods, 2023 to 2033

Figure 59: Latin America Market Attractiveness by Service Type Provider , 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Western Europe Market Value (US$ Million) by Phase of Drug Development, 2023 to 2033

Figure 62: Western Europe Market Value (US$ Million) by Type of Methods, 2023 to 2033

Figure 63: Western Europe Market Value (US$ Million) by Service Type Provider , 2023 to 2033

Figure 64: Western Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Western Europe Market Value (US$ Million) Analysis by Phase of Drug Development, 2018 to 2033

Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Phase of Drug Development, 2023 to 2033

Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Phase of Drug Development, 2023 to 2033

Figure 71: Western Europe Market Value (US$ Million) Analysis by Type of Methods, 2018 to 2033

Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Type of Methods, 2023 to 2033

Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Type of Methods, 2023 to 2033

Figure 74: Western Europe Market Value (US$ Million) Analysis by Service Type Provider , 2018 to 2033

Figure 75: Western Europe Market Value Share (%) and BPS Analysis by Service Type Provider , 2023 to 2033

Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by Service Type Provider , 2023 to 2033

Figure 77: Western Europe Market Attractiveness by Phase of Drug Development, 2023 to 2033

Figure 78: Western Europe Market Attractiveness by Type of Methods, 2023 to 2033

Figure 79: Western Europe Market Attractiveness by Service Type Provider , 2023 to 2033

Figure 80: Western Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: Eastern Europe Market Value (US$ Million) by Phase of Drug Development, 2023 to 2033

Figure 82: Eastern Europe Market Value (US$ Million) by Type of Methods, 2023 to 2033

Figure 83: Eastern Europe Market Value (US$ Million) by Service Type Provider , 2023 to 2033

Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Phase of Drug Development, 2018 to 2033

Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Phase of Drug Development, 2023 to 2033

Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Phase of Drug Development, 2023 to 2033

Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Type of Methods, 2018 to 2033

Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Type of Methods, 2023 to 2033

Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Type of Methods, 2023 to 2033

Figure 94: Eastern Europe Market Value (US$ Million) Analysis by Service Type Provider , 2018 to 2033

Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by Service Type Provider , 2023 to 2033

Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by Service Type Provider , 2023 to 2033

Figure 97: Eastern Europe Market Attractiveness by Phase of Drug Development, 2023 to 2033

Figure 98: Eastern Europe Market Attractiveness by Type of Methods, 2023 to 2033

Figure 99: Eastern Europe Market Attractiveness by Service Type Provider , 2023 to 2033

Figure 100: Eastern Europe Market Attractiveness by Country, 2023 to 2033

Figure 101: South Asia and Pacific Market Value (US$ Million) by Phase of Drug Development, 2023 to 2033

Figure 102: South Asia and Pacific Market Value (US$ Million) by Type of Methods, 2023 to 2033

Figure 103: South Asia and Pacific Market Value (US$ Million) by Service Type Provider , 2023 to 2033

Figure 104: South Asia and Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: South Asia and Pacific Market Value (US$ Million) Analysis by Phase of Drug Development, 2018 to 2033

Figure 109: South Asia and Pacific Market Value Share (%) and BPS Analysis by Phase of Drug Development, 2023 to 2033

Figure 110: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Phase of Drug Development, 2023 to 2033

Figure 111: South Asia and Pacific Market Value (US$ Million) Analysis by Type of Methods, 2018 to 2033

Figure 112: South Asia and Pacific Market Value Share (%) and BPS Analysis by Type of Methods, 2023 to 2033

Figure 113: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Type of Methods, 2023 to 2033

Figure 114: South Asia and Pacific Market Value (US$ Million) Analysis by Service Type Provider , 2018 to 2033

Figure 115: South Asia and Pacific Market Value Share (%) and BPS Analysis by Service Type Provider , 2023 to 2033

Figure 116: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Service Type Provider , 2023 to 2033

Figure 117: South Asia and Pacific Market Attractiveness by Phase of Drug Development, 2023 to 2033

Figure 118: South Asia and Pacific Market Attractiveness by Type of Methods, 2023 to 2033

Figure 119: South Asia and Pacific Market Attractiveness by Service Type Provider , 2023 to 2033

Figure 120: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033

Figure 121: East Asia Market Value (US$ Million) by Phase of Drug Development, 2023 to 2033

Figure 122: East Asia Market Value (US$ Million) by Type of Methods, 2023 to 2033

Figure 123: East Asia Market Value (US$ Million) by Service Type Provider , 2023 to 2033

Figure 124: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 125: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 126: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 127: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 128: East Asia Market Value (US$ Million) Analysis by Phase of Drug Development, 2018 to 2033

Figure 129: East Asia Market Value Share (%) and BPS Analysis by Phase of Drug Development, 2023 to 2033

Figure 130: East Asia Market Y-o-Y Growth (%) Projections by Phase of Drug Development, 2023 to 2033

Figure 131: East Asia Market Value (US$ Million) Analysis by Type of Methods, 2018 to 2033

Figure 132: East Asia Market Value Share (%) and BPS Analysis by Type of Methods, 2023 to 2033

Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Type of Methods, 2023 to 2033

Figure 134: East Asia Market Value (US$ Million) Analysis by Service Type Provider , 2018 to 2033

Figure 135: East Asia Market Value Share (%) and BPS Analysis by Service Type Provider , 2023 to 2033

Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Service Type Provider , 2023 to 2033

Figure 137: East Asia Market Attractiveness by Phase of Drug Development, 2023 to 2033

Figure 138: East Asia Market Attractiveness by Type of Methods, 2023 to 2033

Figure 139: East Asia Market Attractiveness by Service Type Provider , 2023 to 2033

Figure 140: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 141: Middle East and Africa Market Value (US$ Million) by Phase of Drug Development, 2023 to 2033

Figure 142: Middle East and Africa Market Value (US$ Million) by Type of Methods, 2023 to 2033

Figure 143: Middle East and Africa Market Value (US$ Million) by Service Type Provider , 2023 to 2033

Figure 144: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033

Figure 145: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 146: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 147: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 148: Middle East and Africa Market Value (US$ Million) Analysis by Phase of Drug Development, 2018 to 2033

Figure 149: Middle East and Africa Market Value Share (%) and BPS Analysis by Phase of Drug Development, 2023 to 2033

Figure 150: Middle East and Africa Market Y-o-Y Growth (%) Projections by Phase of Drug Development, 2023 to 2033

Figure 151: Middle East and Africa Market Value (US$ Million) Analysis by Type of Methods, 2018 to 2033

Figure 152: Middle East and Africa Market Value Share (%) and BPS Analysis by Type of Methods, 2023 to 2033

Figure 153: Middle East and Africa Market Y-o-Y Growth (%) Projections by Type of Methods, 2023 to 2033

Figure 154: Middle East and Africa Market Value (US$ Million) Analysis by Service Type Provider , 2018 to 2033

Figure 155: Middle East and Africa Market Value Share (%) and BPS Analysis by Service Type Provider , 2023 to 2033

Figure 156: Middle East and Africa Market Y-o-Y Growth (%) Projections by Service Type Provider , 2023 to 2033

Figure 157: Middle East and Africa Market Attractiveness by Phase of Drug Development, 2023 to 2033

Figure 158: Middle East and Africa Market Attractiveness by Type of Methods, 2023 to 2033

Figure 159: Middle East and Africa Market Attractiveness by Service Type Provider , 2023 to 2033

Figure 160: Middle East and Africa Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Pharmacy Refrigerators Market

Published : July 2022

Packaging

Prescription Pharmacy Bags Market

Published : July 2021

Explore Healthcare Insights

View Reports